Cancer Drugs– tag –
-
ecDNA in Glioblastoma: Spatial Heterogeneity and EGFRvIII Evolution (Part 2)
This Part focuses on how extrachromosomal DNA (ecDNA) shapes spatial heterogeneity and evolution in glioblastoma (GBM). We outline the extreme copy-number gains of drivers (EGFR/PDGFRA/CDK4) on ecDNA, region-to-region response gaps, and ... -
ecDNA in Cancer: Mechanisms of Diversity and Resistance (Part 1)
Extrachromosomal DNA (ecDNA) reshapes oncogene dosage, transcription, phenotypes, and spatial organization, thereby accelerating intratumor heterogeneity and therapy resistance. In Part 1, we briefly introduce non-GBM evidence up front a... -
KRAS Special Series Part 8 (Final): The Next Decade — From Cancer Control to Regeneration and Longevity
For over four decades, KRAS symbolized the “undruggable.” By the mid-2020s, it became the flagship of precision oncology. This final chapter summarizes that evolution—from structural biology to AI-driven therapeutics—and looks ahead to h... -
KRAS Special Series Part 7: The Biotech Frontline — How RAS Drug Discovery Is Being Redefined
The race to drug KRAS is reshaping not only science but the entire biotech ecosystem. Once deemed “undruggable,” KRAS became a proving ground for startups, academic spinouts, and AI-driven discovery. This part reviews key players—Revolut... -
KRAS Special Series Part 6: Beyond Resistance — Wild-Type and Mutant RAS Co-Inhibition and the Dawn of Systems RAS Therapy
The rise of KRAS inhibitors marked the end of the “undruggable” era—but tumors adapt swiftly. Resistance often stems from a cooperative reactivation between mutant and wild-type RAS. This sixth installment dissects the molecular basis of... -
KRAS Special Series Part 5: The New Wave of KRAS Drug Discovery — Degraders, RAS(ON) Inhibitors, and AI-Driven Design
KRAS has evolved from the icon of “undruggable” to the engine of next-generation oncology. Building on the success of allele-selective inhibitors (e.g., G12C), the mid-2020s ushered in three powerful paradigms: RAS(ON) inhibition, pan-KR... -
KRAS Special Series Part 4: Immunity, Aging, and Regeneration — The Future of Life Regulation Through KRAS Signaling
KRAS research has now transcended oncology. Recent studies reveal that KRAS signaling interconnects with immunity, cellular aging, and even regenerative medicine. In this fourth installment, we redefine KRAS as a “life regulator” rather ... -
KRAS Special Series Part 3: The Silent Ally — How Wild-Type KRAS Builds Resistance Networks
As KRAS-targeted therapy enters a new era, one unexpected player has captured the spotlight: Wild-type KRAS (WT-KRAS). While mutant KRAS has long been seen as the dominant oncogenic driver, emerging evidence shows that its wild-type coun... -
KRAS Special Series Part 2: What Each Allele Tells Us — Biological and Clinical Diversity of G12D, G12V, G12R, and Q61
In Part 1, we traced the long struggle to target KRAS and the breakthrough that made the “undruggable” druggable. Now we turn to a crucial question: how do different KRAS alleles shape tumor biology, signaling behavior, and clinical outc... -
KRAS Special Series Part 1: The Rise, Fall, and Rebirth of the “Undruggable” Target
Few oncogenes have shaped the landscape of cancer research as profoundly as KRAS. Since the first RAS mutation was identified in human bladder cancer cells in 1982, this small GTP-binding protein has fascinated scientists as both a myste... -
Part 2｜Inside AMPLIFY-201 Final Analysis: What the KRAS Vaccine Is Actually Moving
Takeaway: Lymph-node–targeted amphiphile delivery achieved robust dual CD4/CD8 responses. A data-driven ~9.17× immune threshold aligned with RFS/OS gains and ctDNA negativity in the adjuvant MRD setting. Contents 1. One-Minute Summary 2.... -
[2025 Oct] KRAS Cancer Vaccine Competitive Map｜Elicio, SLATE-KRAS & Academic SLP Compared (Adjuvant MRD × Off-the-Shelf Era)
Takeaway: the field is coalescing around shared neoantigens × off-the-shelf × adjuvant MRD. Elicio (ELI-002 7P) leads the pack; academic SLP + poly-ICLC programs and Gritstone’s SLATE-KRAS follow. With V941 halted, the landscape is clear... -
Oncology Drug Approval News Flash: FDA Approves Lurbinectedin Plus Atezolizumab for Maintenance in Extensive-Stage Small Cell Lung Cancer
On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) in combination with atezolizumab (Tecentriq, Genentech) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) fo... -
Oncology Drug Approval News Flash: FDA Approves Imlunestrant (Inluriyo) for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer
On September 25, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s estrogen receptor antagonist Imlunestrant (Inluriyo) for the treatment of adult patients with ER-positive, HER2-negative, ESR1-mutated advanced or me... -
China Biopharma Deals, 2019–2025: Part 1 — Oncology (ADC, Bispecifics, IO, Cell Therapy)
Oncology is the tip of the spear for China-origin innovation in global partnering. This article gives you a bird’s-eye view of the major deals, then goes deep into the operating logic behind ADCs, bispecific antibodies, checkpoint inhibi... -
How Respiratory Viral Infections May Alter Metastatic Risk in Breast Cancer: Latest Evidence and Practical Guidance
Even after successful primary treatment, disseminated cancer cells (DCCs) can persist in a dormant state for years and later “awaken,” leading to overt metastasis. Recent studies suggest that respiratory viral infections—such as influenz... -
The “Dark Side” of NK Cells in Cancer Immunotherapy Part 2: Therapeutic Strategies and Future Outlook
In Part 1, we reviewed mechanisms by which NK cells contribute to resistance against immune checkpoint blockade (ICB). In this follow-up article (Part 2), we discuss the clinical implications, potential strategies, and future directions ... -
The “Dark Side” of NK Cells in Cancer Immunotherapy Part 1: Immunosuppressive Roles and Resistance Mechanisms
Natural killer (NK) cells have long been recognized as frontline effectors of tumor surveillance. However, recent studies reveal that their role within the tumor microenvironment (TME) is far more complex. NK cells are increasingly impli... -
Claudin18.2 ADC Development Part 4: Global Development Landscape and Future Outlook
Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. Beyond SHR-A1904 and IBI343, several other candidates such as CMG901, EO-3021, a... -
Claudin18.2 ADC Development Part 2: Phase 1 Results and Clinical Features of IBI343
In this article, we summarize the phase 1 trial of IBI343, reported in Nature Medicine (July 2025), focusing on its structural innovations, safety, efficacy, and position within the landscape of Claudin18.2-targeted ADCs. Drug Profile: M...
